Editorial: targeting aberrant hepatic inflammation for treatment of non-alcoholic steatohepatitis-authors' reply

Affiliations

¹ The Liver Unit. Hadassah Medical Organization, Hadassah Hebrew University Medical Centre, Jerusalem, Israel.
² The Liver Institute, Rabin Medical Centre, Beilinson Hospital, Petah-Tikva, Israel.
³ Cardiology Department, Holy Family Hospital, Nazareth, Israel.
⁴ Can-Fite BioPharma Ltd, Petah-Tikva, Israel.
⁵ The Radiology Dep. Hadassah Medical Organization, Hadassah Hebrew University Medical Centre, Jerusalem, Israel.
⁶ BioInsight Ltd, Binyamina, Israel.

Editorial

Rifaat Safadi et al. Aliment Pharmacol Ther. 2022 Feb.

. 2022 Feb;55(4):485-486.

doi: 10.1111/apt.16762.

¹ The Liver Unit. Hadassah Medical Organization, Hadassah Hebrew University Medical Centre, Jerusalem, Israel.
² The Liver Institute, Rabin Medical Centre, Beilinson Hospital, Petah-Tikva, Israel.
³ Cardiology Department, Holy Family Hospital, Nazareth, Israel.
⁴ Can-Fite BioPharma Ltd, Petah-Tikva, Israel.
⁵ The Radiology Dep. Hadassah Medical Organization, Hadassah Hebrew University Medical Centre, Jerusalem, Israel.
⁶ BioInsight Ltd, Binyamina, Israel.

No abstract available

Comment on

Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis.
Safadi R, Braun M, Francis A, Milgrom Y, Massarwa M, Hakimian D, Hazou W, Issachar A, Harpaz Z, Farbstein M, Itzhak I, Lev-Cohain N, Bareket-Samish A, Silverman MH, Fishman P. Safadi R, et al. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1405-1415. doi: 10.1111/apt.16664. Epub 2021 Oct 20. Aliment Pharmacol Ther. 2021. PMID: 34671996 Free PMC article. Clinical Trial.
Editorial: targeting aberrant hepatic inflammation for treatment of non-alcoholic steatohepatitis.
Muthiah MD, Siddiqui MS. Muthiah MD, et al. Aliment Pharmacol Ther. 2022 Feb;55(4):483-484. doi: 10.1111/apt.16748. Aliment Pharmacol Ther. 2022. PMID: 35092056 No abstract available.

1. Muthiah MD, Siddiqui M. Editorial: targeting aberrant hepatic inflammation for treatment of nonalcoholic steatohepatitis. Aliment Pharnacol Ther 2022;55:483-484.
1. Safadi R, Braun M, Francis A, et al. Randomised clinical trial: a phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis. Aliment Pharmacol Ther. 2021;54:1405-1415.
1. Stemmer SM, Manojlovic NS, Marinca MV, et al. Namodenoson in advanced hepatocellular carcinoma and Child-Pugh B cirrhosis: randomized placebo-controlled clinical trial. Cancers (Basel). 2021;13:187.
1. Bar-Yehuda S, Stemmer SM, Madi L, et al. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol. 2008;33:287-295.